Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BST-236 in Relapsed or Refractory AML or HR-MDS
NCT04827719Phase 2Completed
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- May 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aspacytarabine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Groupe Français des Myélodysplasies. Started May 2021; status: completed.
02
Drugs
aspacytarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04827719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04827719.